Related Experiment Videos

Antidepressants and risk of first-time hospitalization for myocardial infarction: a population-based case-control

Taco B M Monster1, Søren P Johnsen, Mette L Olsen

  • 1Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus and Aalborg, Denmark. t.monster@home.nl

The American Journal of Medicine
|November 16, 2004
PubMed

Insights

Antidepressant use may reduce the risk of myocardial infarction hospitalization in patients with prior cardiovascular disease. This protective association was observed across different antidepressant classes, suggesting a potential benefit for this patient group.

Area of Science:

  • Cardiology
  • Psychiatry
  • Pharmacology

Background:

  • Depression is linked to increased myocardial infarction (MI) risk.
  • Selective serotonin reuptake inhibitors (SSRIs) have fewer cardiac side effects than older antidepressants.
  • SSRIs may inhibit platelet aggregation, potentially reducing thrombotic events like MI.

Purpose of the Study:

  • To investigate the association between antidepressant use and the risk of first-time MI hospitalization.
  • To compare the risk of MI hospitalization across different classes of antidepressants versus nonuse.
  • To determine if this association differs based on a history of cardiovascular disease.

Main Methods:

  • A population-based case-control study in North Jutland County, Denmark (1994-2002).
  • Identified 8887 MI cases and 88,862 matched controls.
  • Used conditional logistic regression to analyze antidepressant prescriptions prior to MI hospitalization, adjusting for confounders.

Main Results:

  • In patients with a history of cardiovascular disease, antidepressant use was associated with a reduced risk of MI hospitalization.
  • Adjusted odds ratios for MI hospitalization were 0.85 for SSRIs, 0.83 for nonselective serotonin reuptake inhibitors, and 0.55 for other antidepressants.
  • No significant associations were found among individuals without a history of cardiovascular disease.

Conclusions:

  • Antidepressant use may decrease MI hospitalization risk in patients with existing cardiovascular disease.
  • The findings suggest a potential cardioprotective effect of antidepressants in this population.
  • Further research is needed to clarify if specific antidepressant classes offer differential benefits.
Abstract

Related Concept Videos

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...